Abstract
To investigate the efficacy of TP (Toripalimab Plus) chemotherapy combined with karelizumab in the treatment of advanced ovarian cancer after surgery. We recruited 96 patients with advanced ovarian cancer who were admitted to our hospital between December 2019 and December 2022 with advanced ovarian cancer and treated by tumor cell reduction surgery. The patients were randomly divided into groups using a digital table, 48 each. The control group was treated with chemotherapy, while the observation group was treated with chemotherapy combined with karelizumab. We compared the two groups with regards to adverse reactions and the levels of VEGF (Vascular Endothelial Growth Factor), MMP-9 (matrixmetalloproteinase 9), CEA (A Carcinoma Embryonic Antigen), AFP (alpha-fetoprotein), CA125 (carbohydrate antigen 125), CA19-9 (carbohydrate antigen 19-9) and T lymphocytes. There was no significant difference between the two groups with regards to adverse reactions (p > 0.05); the levels of VEGF and MMP-9 in the observation group were lower. There was a significant difference between the data before and after treatment within the same group (all p < 0.05); the levels of CEA, AFP, CA125 and CA19-9 in the observation group were lower than those in the control group, with significant differences before and after treatment within the same group (p < 0.05); the levels of CD3+ (cluster of differentiation 3+) and CD4+ in the observation group were higher, while the levels of CD8+ were lower than those in the control group. There were significant differences before and after treatment in the same group (p < 0.05). The combination of karelizumab and TP chemotherapy had a significant and positive impact on postoperative patients with advanced ovarian cancer by effectively regulating immune function and the levels of tumor markers. This protocol is safe and can be selected by considering the specific situation of individual patients.
Subject
Obstetrics and Gynecology,Oncology